Facebook Users

Will AHPI go up?

AHPI Allied Healthcare Products, Inc. featured news, full reports, and detailed charts

Allied Healthcare Products, Inc. (AHPI) Wrap Up:

Allied Healthcare Products, Inc. (“Allied” or the “Company”) manufactures a variety of respiratory products used in the health care industry in a wide range of hospital and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. The Company’s product lines include respiratory care products, medical gas equipment and emergency medical products. The Company believes that it maintains significant market shares in selected product lines. The Company’s products are marketed under well-recognized and respected brand names to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers and others.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f09%2f28%2f0000950137-07-014817.html#FIS_BUSINESS"   
www.alliedhpi.com
350 Employees
Founded in 1979

Allied Healthcare Products Inc. (AHPI:NASDAQ)

LAST $5.29 USD
CHANGE TODAY +0.298 5.97%
VOLUME 347.0
As of 12:14 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).

Snapshot of Allied Healthcare Products Inc. (AHPI)

OPEN
$5.00
PREVIOUS CLOSE
$4.99
DAY HIGH
$5.29
DAY LOW
$5.00
52 WEEK HIGH
10/26/09 - $6.90
52 WEEK LOW
12/30/08 - $2.52
MARKET CAP
42.8M
AVERAGE VOLUME 3 mo
4.1K
DILUTED EPS TTM
$-2.24
SHARES OUTSTANDING
8.1M
AHPI Does Not Pay Dividends
P/E TTM
NM
K = Thousands  M = Millions  B = Billions

AHPI Top Compensated Officers

Mr. Earl R. Refsland
Chief Executive Officer, President and Direct...
Age: 66
Total Annual Compensation: $391.6K
Mr. Daniel C. Dunn
Chief Financial Officer, Vice President of Fi...
Age: 50
Total Annual Compensation: $189.8K
Mr. Robert B. Harris
Vice President of Operations
Age: 52
Total Annual Compensation: $181.6K
Mr. Eldon P. Rosentrater
Vice President of Administration & Corporate ...
Age: 55
Total Annual Compensation: $172.9K

Executives, Board Directors

Compensation as of Fiscal Year 2009.

Key developments for Allied Healthcare Products Inc. (AHPI)

Allied Healthcare Products Inc. Terminates Revolving Credit Facility Arrangement with Bank of America as Successor to LaSalle Bank National Association

Effective as of November 13, 2009, Allied Healthcare Products Inc. has terminated its revolving credit facility arrangement with Bank of America, N.A., as successor to LaSalle Bank National Association. The old credit agreement provided for borrowings of up to $10,000,000 and was available through September 1, 2010. No loans were outstanding under the old credit agreement as of November 13, 2009. On November 17, 2009, in order to obtain long term financing, the company entered into that certain loan and security agreement by and between Enterprise Bank & Trust and the Company pursuant to which the company obtained a secured revolving credit facility with borrowing availability of up to $7,500,000. The company's obligations under the new credit facility are secured by certain assets of the company pursuant to the terms and subject to the conditions set forth in the new credit agreement. The company also paid a closing fee of $20,000 in order to obtain the new credit facility. The new credit facility will be available on a revolving basis until it expires on November 17, 2010, at which time all amounts outstanding under the new credit facility will be due and payable. Advances under the new credit facility will be made pursuant to that certain revolving credit note executed by the company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 0.50% in excess of Enterprise Bank & Trust's prime-rate based interest rate for commercial loans, subject to a minimum annual interest rate of 4.50%. Interest is computed based on the actual number of days elapsed over a year of 360 days. Advances may be prepaid in whole or in part without premium or penalty. Under the new credit agreement, advances are generally subject to customary borrowing conditions. The new credit agreement also contains covenants with which the company must comply during the term of the new credit facility.

Allied Healthcare Products Inc. Reports Unaudited Consolidated Results for the First Quarter Ended September 30, 2009

Allied Healthcare Products Inc. reported unaudited consolidated results for the first quarter ended September 30, 2009. For the quarter, the company reported loss from operations of $1,188,900, loss before provision for benefit from income taxes of $1,201,343, net loss of $744,938 or $0.09 per diluted share on net sales of $11,323,676 compared to income from operations of $317,467, income before provision for benefit from income taxes of $336,059, net income of $208,357 or $0.03 per diluted share on net sales of $14,441,011 for the same period a year ago.

Allied Healthcare Products Inc., Annual General Meeting, Nov 13, 2009

Allied Healthcare Products Inc., Annual General Meeting, Nov 13, 2009, at 09:00 US Central Time. Location: Corporate Headquarters of Allied Healthcare Products Inc., 1720 Sublette, St. Louis, MO 63110,United States. Agenda: To elect five directors to serve until the next Annual Meeting of stockholders or until their successors are elected and qualified; to ratify the adoption of the Allied Healthcare Products 2009 Incentive Stock Plan for employees; and to transact such other business as may properly come before the meeting or any adjournment thereof.

otc, otcbb, pinksheet, AHPI, ob Allied Healthcare Products, Inc.

AHPI Competitors

Company Last Change
IPC The Hospitalist Co Inc $31.86 USD -0.29
Market data is delayed at least 20 minutes.

Industry Analysis

Valuation AHPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

AHPI

 | 

AHPI transactions

Type
Date
Target
No transactions in the last 6 months.

More Recent News About Allied Healthcare Products, Inc.

More news for AHPI

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations RESULTS OF OPERATIONS Three Months ended December 31, 2008 compared to three months ended December 31, 2007. Allied had net sales of $12.5 million for the three months ended December 31, 2008, down $1.1 million, or 8.1%, from net sales of $13.6 million in the prior year same quarter. Customer orders were $1.4 million lower than the prior year same quarter, purchase order releases were $0.5 million lower than in the prior year same quarter. Purchase order release times depend on the scheduling practices of individual customers, and do vary over time. Sales were also down from the prior year due to a $450,000 decrease in sales recognized as a result of product development activities to pursue development of a new carbon dioxide absorption product. Sales for the three months ended December 31, 2007 include $450,000 as a result of product development activities to pursue development of a new carbon dioxide absorption product. While the Company continues to pursue development of a new product, reimbursement of those activities by Abbott was completed during the quarter ended September 30, 2008. Additional cost to develop the new product during the second quarter of fiscal 2009 was not reimbursed. Sales for the three months ended December 31, 2008 include $172,050 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Sales for the three months ended December 31, 2007 include $116,250 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Income from the agreement will continue to be recognized over eight years, the term of the agreement, at $57,350 per month. Allied continues to sell Carbolime®, a carbon dioxide absorbent with a different formulation than Baralyme®. The...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations RESULTS OF OPERATIONS Three Months ended September 30, 2008 compared to three months ended September 30, 2007. Allied had net sales of $14.4 million for the three months ended September 30, 2008, up $0.3 million, or 2.1%, from net sales of $14.1 million in the prior year same quarter. Customer purchase order releases were $0.3 million lower than in the prior year same quarter. Additionally, customer orders were $0.1 million higher than the prior year same quarter. Purchase order release times depend on the scheduling practices of individual customers, and do vary over time. Domestic sales were up 8.9% from the prior year same quarter, while international business, which represented 16.7% of first quarter sales, was down 21.0%. Orders for the Company's products for the three months ended September 30, 2008 of $13.3 million were $0.1 million or 0.8% higher than orders for the prior year same quarter of $13.2 million. Domestic orders are down 4.2% over the prior year same quarter while international orders which represented 19.0% of first quarter orders were up 28.6%. The Company currently believes that the increase in international orders is a result of order timing, and is not reflective of a gain of market share. Sales for the three months ended September 30, 2008 include $172,500 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Sales for the three months ended September 30, 2008 also include $99,000 as a result of product development activities to pursue development of a new carbon dioxide absorption product. The agreement with Abbott provides for Abbott to pay Allied up to $2,150,000 in product development cost to pursue development of a new carbon dioxide absorption product for use in connection with inhalation anesthetics that does not contain potassium hyd...
Click here to read the whole Article (external link)

Recession-Driven Cuts by Hospitals, Municipalities Lead to 2009 Loss for Allied Healthcare Products

ST. LOUIS, Sept. 25 /PRNewswire-FirstCall/ -- Allied Healthcare Products, Inc., (Nasdaq: AHPI - News) reported that recession-driven budget cuts in its healthcare markets led to a $4.3 million, or 7.6 percent, decrease in sales for 2009 and a net loss for the fiscal year of $2.12 per share, compared to a profit of 11 cents per share in fiscal year 2008. This includes the effect of a non-cash accounting charge of $16.0 million relating to the impairment of goodwill in the fourth quarter ended June 30, 2009. The impairment was identified during the company's annual evaluation of the carrying value of goodwill and reflects the decline of the Allied stock price during the past year and a general downturn in orders, operating profits and cash flows as a result of the current recession. This non-cash charge does not affect operations or cash flow. After this impairment charge, Allied will no longer have a goodwill balance and will not record any additional goodwill impairment.For the quarter ended June 30, 2009, Allied reported a net loss of $16.1 million, or $2.04 per diluted share, on sales of $12.7 million, compared to net income of $0.7 million, or 8 cents per diluted share, for the prior year period. Results for the fourth quarter of 2009 include the $16.0 million charge for impairment of goodwill.Allied sales in domestic hospital and emergency markets suffered most in 2009. The domestic hospital construction market remained flat, reflecting lead times that preceded the recession. Sales to international markets f...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl

Show all filings for ALLIED HEALTHCARE PRODUCTS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for ALLIED HEALTHCARE PRODUCTS INC 25-Sep-2009Results of Operations and Financial Condition, Regulation FD Discl Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All ...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) Adoption of 2009 Incentive Stock Plan by the Board of Directors (subject to stockholder approval) On August 27, 2009 the board of directors (the "Board") of Allied Healthcare Products, Inc. (the "Company") approved a 2009 Incentive Stock Plan (the "2009 ISP") subject to approval by the stockholders of the Company at the 2009 annual meeting of the Company's stockholders. The 2009 ISP is intended to replace the Company's 1999 Incentive Stock Plan, under which no awards could be granted after June 30, 2009. If the Company's stockholders do not approve the 2009 ISP at such meeting, the 2009 ISP, and any incentives granted thereunder, will be null, void and of no legal force or effect. The purpose of the 2009 ISP is to (i) stimulate employees' efforts on the Company's behalf, (ii) maintain and strengthen employees' desire to remain with the Company, (iii) encourage employees to have a greater personal financial investment in the Company through ownership of the Company's common stock, and (iv) aid the Company in recruiting and retaining qualified executive employees. The 2009 ISP provides for the issuance of up to an aggregate of six hundred thousand (600,000) shares of the Company's common stock (subject to adjustment in the event of stock splits, stock dividends, merger, consolidation or other similar events) as non-qualified stock options, incentive stock options, restricted stock, restricted stock units, stock appreciation rights and other stock-based awards. No award may be made under the 2009 ISP after August 27, 2019, but awards granted prior theretofore may extend beyond that date. Each award granted under the 2009 ISP is not transferable other than by will or the laws of descent and distribution, and with respect to stock options, shall be exercisable, during the grantee's lifet...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations RESULTS OF OPERATIONS Three months ended March 31, 2009 compared to three months ended March 31, 2008 Allied had net sales of $12.4 million for the three months ended March 31, 2009, down $1.5 million, or 10.8%, from net sales of $13.9 million in the prior year same quarter. Customer orders were $0.8 million lower than the prior year same quarter. Purchase order releases were $1.9 million lower than in the prior year same quarter. Purchase order release times depend on the scheduling practices of individual customers, and do vary over time. Releases for the quarter are also impacted by year to date orders which are $2.1 million lower than in the prior year. At this time, the Company believes this decrease in orders and releases is due to broad economic conditions and does not represent a decrease in the Company's market share. Sales were also down from the prior year due to a $122,000 decrease in sales recognized as a result of product development activities to pursue development of a new carbon dioxide absorption product. Sales for the three months ended March 31, 2008 include $122,000 as a result of product development activities to pursue development of a new carbon dioxide absorption product. While the Company continues to pursue development of a new product, reimbursement of those activities by Abbott was completed during the quarter ended September 30, 2008. Additional cost to develop the new product during the third quarter of fiscal 2009 was not reimbursed. Sales for the three months ended March 31, 2009 include $171,600 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Sales for the three months ended March 31, 2008 include $116,250 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production...
Click here to read the whole Article (external link)

Recession Continues to Depress Sales at Allied Healthcare Products

ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Recession in domestic and international markets continued to depress sales for Allied Healthcare Products in the first quarter of fiscal year 2010 ending September 30, 2009. Sales declines pushed Allied into a loss for the quarter. The net loss for the quarter was about $745,000, or negative 9 cents per share, compared to a net profit the year earlier of about $208,000, or 3 cents per share.Sales fell about 21 percent in the quarter, from about $14.4 million in the first quarter of last year to $11.3 million in the current quarter.Allied introduced a new product line late in fiscal 2009 - mass casualty ventilators designed for use in pandemics, natural disasters and terrorist attacks. Sales of the new products totaled $500,000 in the quarter.Allied mass casualty ventilators address needs that traditional, full-featured ventilators do not meet, said Earl Refsland, president and chief executive officer. For example, Allied ventilators cost a fraction of the price of full-featured ventilators, can be operated by non-professionals after brief instruction and are rugged, for use in harsh field conditions. Also, Allied mass casualty ventilators have minimal maintenance requirements, making them ideal for government stockpiles, Refsland said.A bright spot in the quarter was strong performance in cost reduction efforts in manufacturing and operations. Most of these savings represent long-term reductions that will continue to benefit the company in future quarters.Allied earnings in the quarter were affected by a non-cash charge of $609,000 resulting from the company's grant to the chief executive officer of an option to purchase 320,000 shares of common stock in the next six years.Allied Healthcare Products, Inc., manufactures a variety of respiratory products used in th...
Click here to read the whole Article (external link)

Allied Healthcare posts Q1 loss

ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations RESULTS OF OPERATIONS Three months ended September 30, 2009 compared to three months ended September 30, 2008 Allied had net sales of $11.3 million for the three months ended September 30, 2009, down $3.1 million, or 21.5%, from net sales of $14.4 million in the prior year same quarter. Customer orders of $11.6 million were $1.7 million lower than the prior year same quarter. Purchase order releases were $3.2 million lower than in the prior year same quarter. Purchase order release times depend on the scheduling practices of individual customers, and do vary over time. $99,000 of the decrease in the Company's sales compared to the same quarter of last year are due to discontinuation of reimbursement from Abbott for product development activities to pursue development of a new carbon dioxide absorption product. Sales for the three months ended September 30, 2008 include $99,000 of such reimbursements. While the Company continues to pursue development of a new product, reimbursement of those activities by Abbott was completed during the quarter ended September 30, 2008. Sales for the three months ended September 30, 2009 include $172,050 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Sales for the three months ended September 30, 2008 include $172,500 for the recognition into income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Income from the agreement will continue to be recognized at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell Carbolime®, a carbon dioxide absorbent with a different formulation than Baralyme®. The Company ceased the sale of Baralyme® on August 27th, 2004. Domestic sales were down 19.8% from the prior...
Click here to read the whole Article (external link)

ALLIED HEALTHCARE PRODUCTS INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

Would you like to leave a comment about Allied Healthcare Products, Inc. AHPI

Besides Allied Healthcare Products, Inc. there is more great information available at Realpennies.com